Cyclooxygenase-mediated prostaglandin F2α is decreased in an elderly population treated with low-dose aspirin

被引:19
作者
Helmersson, J
Vessby, B
Larsson, A
Basua, S
机构
[1] Uppsala Univ, Fac Med, Sect Clin Nutr Res Publ Hlth & Caring Sci, SE-75125 Uppsala, Sweden
[2] Univ Uppsala Hosp, Fac Med, Sect Clin Chem, SE-75125 Uppsala, Sweden
来源
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS | 2005年 / 72卷 / 04期
关键词
D O I
10.1016/j.plefa.2004.10.019
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Low-dose aspirin (acetylsalicylic acid) is used as prophylaxis against cardiovascular diseases. The effect of aspirin on inflammation and oxidative stress, processes known to be involved in cardiovascular diseases, are not fully known. The cyclooxygenase(COX)-mediated inflammatory indicator prostaglandin F-2 alpha (PGF(2 alpha)) (15-keto-dihydro-PGF(2 alpha)), cytokine-mediated inflammatory indicators (interleukin-6, high-sensitivity C-reactive protein, serum amyloid A protein), and oxidative stress indicators (8-iso-PGF(2 alpha), tocopherols) were quantified in men with daily 75 mg of aspirin (n = 175) and control men (n = 464), all of age 77, in a cross-sectional study. Men treated with aspirin had decreased levels of urinary 15-keto-dihydro-PGF(2 alpha) than controls (P < 0.01), independent of possible cardiovascular risk factors. Aspirin-treated men had increased levels of alpha-tocopherol than controls (P < 0.05). This is the first study to indicate that low-dose aspirin treatment is associated with decreased levels of PGF(2 alpha). This observation suggests a possible COX-mediated anti-inflammatory effect of low-dose aspirin, which should be further confirmed by intervention studies. (c) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:227 / 233
页数:7
相关论文
共 51 条
[1]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[2]   Factors regulating isoprostane formation in vivo [J].
Basu, S ;
Helmersson, J .
ANTIOXIDANTS & REDOX SIGNALING, 2005, 7 (1-2) :221-235
[3]   ENDOGENOUS INHIBITION OF ARACHIDONIC-ACID METABOLISM IN THE ENDOMETRIUM OF THE SHEEP [J].
BASU, S .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1989, 35 (03) :147-152
[4]   DEVELOPMENT OF A CONTINUOUS BLOOD COLLECTION TECHNIQUE AND A DETAILED STUDY OF PROSTAGLANDIN-F2-ALPHA RELEASE DURING LUTEOLYSIS AND EARLY-PREGNANCY IN HEIFERS [J].
BASU, S ;
KINDAHL, H .
JOURNAL OF VETERINARY MEDICINE SERIES A-PHYSIOLOGY PATHOLOGY CLINICAL MEDICINE, 1987, 34 (07) :487-500
[5]   Oxidative injury and survival during endotoxemia [J].
Basu, S ;
Eriksson, M .
FEBS LETTERS, 1998, 438 (03) :159-160
[6]   Oxidative injury induced cyclooxygenase activation in experimental hepatotoxicity [J].
Basu, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 254 (03) :764-767
[7]   Radioimmunoassay of 15-keto-13,14-dihydro-prostaglandin F2α:: an index for inflammation via cyclooxygenase catalysed lipid peroxidation [J].
Basu, S .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1998, 58 (05) :347-352
[8]  
BASU S, 1998, FATTY ACIDS, V58, P319
[9]   PROSTAGLANDINS - MEMBERS OF A NEW HORMONAL SYSTEM [J].
BERGSTROM, S .
SCIENCE, 1967, 157 (3787) :382-+
[10]   Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men [J].
Byberg, L ;
Siegbahn, A ;
Berglund, L ;
McKeigue, P ;
Reneland, R ;
Lithell, H .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (02) :258-264